Magenta Therapeutics Appoints Anne McGeorge to Board of Directors
16 July 2019 - - US-based biotechnology company Magenta Therapeutics (NASDAQ: MGTA) has appointed Anne McGeorge, M.S., CPA, to its board of directors, the company said.
McGeorge will also serve as chair of the Magenta audit committee.
McGeorge is an operating partner at Havencrest Healthcare, a growth equity fund specializing in the healthcare industry; and a board member at Dioko Health Ventures, a healthcare venture fund.
She previously spent more than a decade as managing partner of the US and Global Healthcare practice at Grant Thornton, an independent audit, tax and advisory firm; and prior to that was a healthcare partner at audit and tax firms Deloitte, LLP and Arthur Andersen, LLP.
McGeorge is a member of the board of directors and the audit/finance and new technology committees of Be The Match, a non-profit organization dedicated to helping patients access life-saving stem cell transplants.
She also sits on the steering committee of the Carolinas and Tampa Bay chapters of 2020 Women on Boards, an organization focused on increasing diversity on public company boards.
McGeorge teaches a financial leadership course at the University of North Carolina, Chapel Hill, Gillings School of Public Health.
McGeorge earned a B.B.A. in accounting from the College of William and Mary, and an M.S. in Accounting from the University of Virginia.
Headquartered in Cambridge, Mass., Magenta Therapeutics is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune diseases, blood cancers and genetic diseases.